M
Marianne Just
Researcher at Praxis
Publications - 49
Citations - 1984
Marianne Just is an academic researcher from Praxis. The author has contributed to research in topics: Breast cancer & Trastuzumab. The author has an hindex of 14, co-authored 39 publications receiving 1246 citations.
Papers
More filters
Journal ArticleDOI
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Sandra M Swain,Sandra M Swain,David Miles,Sung Bae Kim,Young-Hyuck Im,Seock-Ah Im,Vladimir Semiglazov,Eva Ciruelos,Andreas Schneeweiss,Sherene Loi,Estefania Monturus,Emma Clark,Adam Knott,Eleonora Restuccia,Mark C. Benyunes,Javier Cortes,Richy Agajanian,Rizvana Ahmad,Bahriye Aktas,Victor Hugo Alencar,Dino Amadori,Jurandyr Andrade,Fabio Franke,Catia Angiolini,Kenjiro Aogi,Jess Armor,Wichit Arpornwirat,Laura Assersohn,William Audeh,Walter E. Aulitzky,Sergio J Azevedo,Maria Alejandra Bartoli,Norberto Batista Lopez,María Bianconi,Laura Biganzoli,Ruemu E. Birhiray,Marianna Bitina,Ron Blachy,Kimberly L. Blackwell,Rita Blanchard,Paulette Blanchet,Ion Boiangiu,Barbara Bower,Christine Brezden-Masley,Adam Brufsky,Leanne Budde,Priscilla Caguioa,Lourdes Calvo,Mario Campone,Robert R. Carroll,Hugo Castro,Valorie Chan,Veena Charu,Saverio Cinieri,Michael R. Clemens,Emilio Alba Conejo,Eduardo Côrtes,Bruno Coudert,Eduardo Cronemberger,Daniel Cubero,Shaker R. Dakhil,Brooke R. Daniel,Neville Davidson,Maria De Fatima Gaui,Susana De La Cruz,Maria Del Pilar,Gilson Delgado,John Allan Ellerton,Cesar Estuardo,Louis Fehrenbacher,Jean-Marc Ferrero,Patrick J. Flynn,Malgorzata Foszczynska-Kloda,Sandra Franco,Hirofumi Fujii,Chris Gallagher,Teresa Gamucci,Nora Giacomi,Miguel Gil I Gil,Antonio Gonzalez Martin,Vera Gorbunova,Eugeny Gotovkin,Nathan B. Green,Elza Grincuka,Eva-Maria Grischke,Vincent Hansen,Jeffrey Hargis,Maik Hauschild,Roberto Hegg,Carolyn B. Hendricks,Robert Hermann,Paulo M. Hoff,Jun Horiguchi,Javier Hornedo Muguiro,Stefano Iacobelli,Kenichi Inoue,Gustavo Ismael,Yoshinori Itoh,Hiroji Iwata,Davi Jendiroba,Rosa Jochim,Alison Jones,Marianne Just,Andre Kallab,Mark Karwal,Masahiro Kashiwaba,Giraldo Kato,Peter A. Kaufman,Pirkko Kellokumpu-Lehtinen,Andreas Kirsch,Igor Kiselev,Paula Klein,Norio Kohno,Mikhail Kopp,Liljana Kostovska-Maneva,Mauricio Kotliar,Iveta Kudaba,Sherko Kümmel,Katsumasa Kuroi,Juan Lacava,Luciano Latini,Soo-Chin Lee,Mikhail Lichinitser,Christopher Lobo,Christoph Maintz,Jedzada Maneecahvakajorn,Alexander Marmé,Gloria Martinez,Norikazu Masuda,Mario Matwiejuk,Vladimir Merculov,Richard A. Michaelson,Luis Miguel,Hernandez Monroy,Filippo Montemurro,Serafin Morales,Rodrigo Moura,Volkmar Mueller,Clive Mulatero,Kazuhiko Nakagami,Takahiro Nakayama,Jeff Neidhart,An Nguyen,Reiki Nishimura,Haruki Ogata,S O'Reilly,Timothy J. O'Rourke,Douglas Otero Reye,Xuenong Ouyang,Ravi Patel,Taral Patel,Jose Luiz Pedrini,Rodrigo Pereira,Alejandra Perez,Carol Peterson,Tadeusz Pienkowski,Helio Pinczowski,Jonathan Polikoff,Wojciech Polkowski,Paola Edith Price,Sue Prill,Frank Priou,Gunta Purkalne,Seppo Pyrhoenen,Robert Quackenbush,Yoshiaki Rai,Nuria Ribelles,Jungsil Ro,Anne Robinson,Robert Robles,Gladys Rodriguez,L Roman,Shigehira Saji,Pedro Sánchez-Rovira,Nobuaki Sato,Marcus Schmidt,Claudia Schumacher,Frank Senecal,Priyanka Sharma,Zhenzhou Shen,Vadim Shirinkin,Edda Simoncini,Thitiya Sirisinha,Raymond Smith,Joohyuk Sohn,Zeljko Soldic,Tania Soria,Darcy Spicer,Vichien Srimuninnimit,Virote Sriuranpong,Elżbieta Starosławska,Petar Stefanovski,Patrapim Sunpaweravong,Julie Taguchi,Koji Takeda,Gabriel Tellez-Trevilla,Randall Thomas,Christoph Thomssen,Zetina Toache,Yutaka Tokuda,Piotr Tomczak,Celia Tosello,Koichiro Tsugawa,Dennis Tudtud,Takayuki Ueno,Brigitte Van Eyll,Mirta Varela,Nikola Vasev,Damir Vrbanec,Xiaojia Wang,Liwei Wang,Junichiro Watanabe,David Waterhouse,Birgitta Wesenberg,Duncan Wheatley,Zee Wan Wong,Sanjay Yadav,Denise A. Yardley,Tsz-Kok Yau,Winnie Yeo,Cheng Ying,Do Youn Oh +221 more
TL;DR: The end-of-study analysis of CLEOPATRA found progression-free and overall survival were significantly improved in the pertuzumab group compared with the placebo group, and the overall survival rates were also significantly improved.
Journal ArticleDOI
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial
Michael Untch,Christian Jackisch,Andreas Schneeweiss,B. Conrad,Bahriye Aktas,Carsten Denkert,Holger Eidtmann,Hermann Wiebringhaus,Sherko Kümmel,Jörn Hilfrich,Mathias Warm,Stefan Paepke,Marianne Just,Claus Hanusch,John Hackmann,Jens-Uwe Blohmer,Michael R. Clemens,Silvia Darb-Esfahani,Wolfgang D. Schmitt,Serban-Dan Costa,Bernd Gerber,Knut Engels,Valentina Nekljudova,Sibylle Loibl,Gunter von Minckwitz +24 more
TL;DR: The GeparSepto (GBG 69) trial assessed whether weekly nab-paclitaxel could increase the proportion of patients achieving pathological complete response compared with weekly solvent-based pac Litaxel, both followed by epirubicin plus cyclophosphamide as neoadjuvant treatment.
Journal ArticleDOI
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment
Oleg Gluz,Ulrike Nitz,Matthias Christgen,Ronald E. Kates,Steven Shak,Michael J. Clemens,Stefan Kraemer,Bahriye Aktas,Sherko Kuemmel,Toralf Reimer,M Kusche,V. Heyl,F Lorenz-Salehi,Marianne Just,Daniel Hofmann,Tom Degenhardt,Cornelia Liedtke,Christer Svedman,Rachel Wuerstlein,Hans Kreipe,Nadia Harbeck +20 more
TL;DR: The substantial discordance observed between traditional prognostic markers and RS emphasizes the need for standardized assessment and supports the potential integration of standardized, well-validated genomic assays such as RS with clinicopathologic prognostic factors for chemotherapy indication in early hormone receptor-positive breast cancer.
Journal ArticleDOI
Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer - A Substudy of the Neoadjuvant GeparQuinto Trial
Yasmin Issa-Nummer,Silvia Darb-Esfahani,Sibylle Loibl,Georg Kunz,Valentina Nekljudova,Iris Schrader,Bruno Valentin Sinn,Hans-Ullrich Ulmer,Ralf Kronenwett,Marianne Just,Thorsten Kühn,Kurt Diebold,Michael Untch,Frank Holms,Jens-Uwe Blohmer,Jörg-Olaf Habeck,Manfred Dietel,Friedrich Overkamp,Petra Krabisch,Gunter von Minckwitz,Carsten Denkert +20 more
TL;DR: The lymphocytic infiltrate is a promising additional parameter for histopathological evaluation of breast cancer core biopsies and prospectively validated in an independent cohort that an increased immunological infiltrate in breast tumor tissue is predictive for response to anthracycline/taxane-based NACT.
Journal ArticleDOI
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
Carsten Denkert,Fenja Seither,Andreas Schneeweiss,Theresa Link,Jens-Uwe Blohmer,Marianne Just,Pauline Wimberger,A Forberger,Hans Tesch,Christian Jackisch,Sabine Schmatloch,Mattea Reinisch,Erich Solomayer,Wolfgang D. Schmitt,Claus Hanusch,Peter A. Fasching,Kristina Lübbe,Christine Solbach,Jens Huober,Kerstin Rhiem,Frederik Marmé,Toralf Reimer,Marcus Schmidt,Bruno Valentin Sinn,Wolfgang Janni,Elmar Stickeler,Laura Michel,Oliver Stötzer,Eric Hahnen,Jenny Furlanetto,Sabine Seiler,Valentina Nekljudova,Michael Untch,Sibylle Loibl +33 more
TL;DR: In this article, the authors compared the clinical and molecular characteristics of HER2-low-positive and HER2zero breast cancer, including response to neoadjuvant chemotherapy and prognosis.